KT-621 is an investigational first-in-class once-daily, oral STAT6 degrader with dupilumab-like activity ... biologics with the convenience of oral administration, which, in turn, can transform ...

Following receipt of dupilumab for 24 weeks, desensitization to peanut exposure in most children/adolescents with peanut allergy was not achieved, according to study results. Image: Adobe Stock ...